Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: Experience of the Intergruppo Italiano Linfomi

Cancer

Volumn 101, Issue 7, 2004, Pages 1601-1608

  Morabito, Fortunato ^a   Gallamini, Andrea ^b   Stelitano, Caterina ^a   Callea, Vincenzo ^a   Guglielmi, Cesare ^c   Neri, Santo ^d   Lazzaro, Antonio ^e   Orsucci, Lorella ^f   Ilariucci, Fiorella ^g   Sacchi, Stefano ^h   Vitolo, Umberto ^f   Federico, Massimo ^h  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Gruppo Italiano Linfomi Trial Office   (Italy)

^e Ospedale Civile   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g Dipartimento di Patologia Clinica   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Clinical outcome; Diffuse large B cell lymphoma; Immunophenotype; Peripheral T cell lymphoma, unspecified; Prognosis

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; T CELL LYMPHOMA;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 4844223242     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20531     Document Type: Review

References (30)

1. Greer JP, York JC, Cousar JB, et al. Peripheral T cell lymphoma: a clinicopathologic study of 42 cases. J Clin Oncol. 1984;2:788-794.
2. Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH 84 regimen. Ann Oncol. 1990;1:45-50.
3. Melnyk A, Rodriguez A, Pugh WC, et al. Evaluation of the Revised European-American Lymphoma Classification confirm the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood. 1997; 89:4514-4520.
4. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
5. Lennert K, Feller AC. Histopathology of non-Hodgkin lymphoma (based on the updated Kiel classification). Berlin: Springer-Verlag, 1992.
6. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal fom from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
7. Stansfeld AG, Diebold J, Kapancy Y, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-293.
8. Jaffe ES, Harris NL, Stein H, et al., editors. Tumours of haematopoietic and lymphoid tissues: pathology and genetics. World Health Organization classification of tumours. Lyon: IARC Press, 2001.
9. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998;92:76-82.
10. Kwak LW, Wilson M, Weiss LM, et al. Similar outcome of treatment of B-cell and T-cell diffuse large cell lymphomas: the Stanford experience. J Clin Oncol. 1991;9:1426-1431.
11. Cheng AL, Chen YC, Wang CH, et al. Direct comparison of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades. Should peripheral T-cell lymphoma be considered separately? J Clin Oncol. 1989;7: 725-731.
12. Lippman SM, Miller TP, Spier CM, et al. The prognostic significance of the immunophenotype in diffuse large cell lymphomas: a comparative study of the T-cell and B-cell phenotype. Blood. 1988;72:436-441.
13. Karakas T, Bergman L, Stutte HJ, et al. Peripheral T-cell lymphomas respond well to vincristine, Adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have similar outcome as high grade B-cell lymphomas. Leuk Lymphoma. 1996;24:121-129.
14. Montalban C, Obeso G, Gallego A, et al. Peripheral T-cell lymphomas: a clinicopathological study of 41 cases and evaluation of the prognostic significance of the updated Kiel classification. Histopathology. 1993;22:303-310.
15. Noorduyn LA, Van der Valk P, Van Heerde P, et al. Stage is a better prognostic indicator than morphologic subtype in primary noncutaneous T-cell lymphoma. Am J Clin Pathol. 1990;93:49-57.
16. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the REAL Classification. Ann Oncol. 1997;8:583-592.
17. Zaja F, Russo D, Silvestri F, et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica 1997;82:171-177.
18. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification. Ann Oncol. 1998;9:849-855.
19. Longo G, Fiorani C, Sacchi S, et al. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Haematologica 1999;84:425-430.
20. Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13:140-149.
21. Musson R, Radstone CR, Horsman JM, et al. Peripheral T cell lymphoma: the Sheffield Lymphoma Group experience (1977-2001). Int J Oncol. 2003;22:1363-1368.
22. Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the Revised European American Lymphoma Classification. Leuk Lymphoma. 2003;44:241-249.
23. Pellatt J, Sweetenham J, Pickering RM, et al. A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann Hematol. 2002;81:267-272.
24. Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American Lymphoma (REAL) Classification. Eur J Cancer. 2002;38:75-81.
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
26. Ansell MS, Habermann TM, Kurtin PJ, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol. 1997; 15:2296-2301.
27. Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia. 2003;17:1948-1960.
28. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004; 103:2474-2479.
29. Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120:978-985.
30. Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2 and activated T-cell marker, and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood. 2004; 103:236-241.